<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9616">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05694286</url>
  </required_header>
  <id_info>
    <org_study_id>852212</org_study_id>
    <nct_id>NCT05694286</nct_id>
  </id_info>
  <brief_title>A Prospective Evaluation of Infraorbital Filler Injection</brief_title>
  <official_title>A Prospective Evaluation of Infraorbital Filler Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to measure the facial volumetric changes over time in&#xD;
      patients injected with hyaluronic acid dermal filler (Juvéderm Volbella XC) in the&#xD;
      infraorbital (under eye) region. Participants will be injected with Juvéderm Volbella XC&#xD;
      filler and asked to return for 3D photography at 2 weeks, 1 month, and 3 months&#xD;
      post-injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Undereye or infraorbital hollowing is a result of a loss of volume causing shadowing and&#xD;
      darkness of the infraorbital region often interpreted as a tired, stressed, and aged&#xD;
      appearance.&#xD;
&#xD;
      The goal of this clinical trial is to measure the facial volumetric changes over time in&#xD;
      patients injected with hyaluronic acid dermal filler (Juvéderm Volbella XC) in the&#xD;
      infraorbital (under eye) region. Participants will be injected with Juvéderm Volbella XC&#xD;
      filler and asked to return for 3D photography and to complete a validated patient&#xD;
      satisfaction questionnaire at 2 weeks, 1 month, and 3 months post-injection. 3D&#xD;
      photogrammetry technology allows for high level feature enhancement and microscopic&#xD;
      anatomical evaluation that was not previously possible and can be used to make volumetric&#xD;
      measurements at injection sites to evaluating minimally invasive injection efficacy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 6, 2023</start_date>
  <completion_date type="Anticipated">June 17, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric change in infraorbital treatment</measure>
    <time_frame>Day 0 pre-intervention, Day 0 post-intervention, Day 14, Day 30, Day 90</time_frame>
    <description>3D facial imaging to measure volumetric changes in the infraorbital region</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction with validated the questionnaire FACE-Q</measure>
    <time_frame>Day 0 pre-intervention, Day 0 post-intervention, Day 14, Day 30, Day 90</time_frame>
    <description>Patient Satisfaction with validated the questionnaire FACE-Q</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Dermal Filler</condition>
  <condition>Rejuvenation</condition>
  <arm_group>
    <arm_group_label>Infraorbital Filler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receives 1-2mL injection of approved filler in infraorbital region</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Juvederm Volbella XC hyaluronic acid dermal filler injection</intervention_name>
    <description>Infraorbital filler injection</description>
    <arm_group_label>Infraorbital Filler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  female&#xD;
&#xD;
          -  age 22 to 65&#xD;
&#xD;
          -  interested in filler injections to reduce undereye volume loss&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  male&#xD;
&#xD;
          -  age &lt;22 or &gt;65&#xD;
&#xD;
          -  prior undereye filler&#xD;
&#xD;
          -  filler/neurotoxin injection within the past 12 months&#xD;
&#xD;
          -  prior facial cosmetic surgery&#xD;
&#xD;
          -  prior facial trauma&#xD;
&#xD;
          -  planned dental work within next 2 weeks&#xD;
&#xD;
          -  travel 1 week prior or 2 weeks after injection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivona Percec, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>January 11, 2023</study_first_submitted>
  <study_first_submitted_qc>January 11, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2023</study_first_posted>
  <last_update_submitted>February 23, 2023</last_update_submitted>
  <last_update_submitted_qc>February 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Ivona Percec</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>injectables</keyword>
  <keyword>tear trough rejuvenation</keyword>
  <keyword>aesthetic improvement</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

